News Releases

Advanced Search
  • Dec 21, 2020
    Update on Phase 3 Clinical Trials and Near Term Operations

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, issued a year-end...

  • Nov 9, 2020

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced today that the final patient...

  • Oct 28, 2020
    Last Patient, Last Visit Anticipated in November 2020

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced today that its joint...

  • Oct 21, 2020

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...

  • Oct 14, 2020

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced today that enrollment in the...

Show 5102550100 per page